Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Oncotype DX 21-Gene Recurrence Score

Oncotype DX is a 21-gene genomic assay that calculates a Recurrence Score (RS) from 0-100 for early-stage HR+/HER2- breast cancer, predicting distant recurrence risk and chemotherapy benefit.

Evidence-based context for fast calculator use

Purpose:
Predict distant recurrence risk and determine chemotherapy benefit in early breast cancer
Population:
HR+/HER2- early-stage breast cancer (node-negative or 1-3 positive nodes)
Factors:
16 cancer-related genes, 5 reference genes, Recurrence Score 0-100
Reference:
Sparano et al., NEJM 2018 (TAILORx)
HomeOncotype DX Recurrence Score Calculator — Breast Cancer Genomic Risk
Pin your most used calculators here by clicking the star in the dropdown.

Oncotype DX Recurrence Score Calculator — Breast Cancer Genomic Risk

Clinical Context & Background

The Oncotype DX Breast Recurrence Score test predicts the benefit of chemotherapy in ER+, HER2- early breast cancer. This tool interprets the score based on age and nodal status, referencing pivotal data from the TAILORx (Node Negative) and RxPONDER (Node Positive 1-3) trials.
Primary Source EvidenceSparano JA, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018;379(2):111-121. (TAILORx); Kalinsky K, et al. N Engl J Med. 2021;385:2336-2347. (RxPONDER)
Formula Logic
Lookup based on Score (0-100), Age, and Nodal Status.

Reference Data

RS RangeNodal StatusChemo Benefit
0 - 25N0 (Age > 50)No Benefit
0 - 15N0 (Age ≤ 50)No Benefit
16 - 25N0 (Age ≤ 50)Some Benefit (~6-9% in 21-25 range)
26 - 100AnyClear Benefit
0 - 25N1 (1-3 nodes)Premenopausal: Benefit. Postmenopausal: No Benefit.

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Oncotype DX Recurrence Score Calculator — Breast Cancer Genomic Risk when interpret your Oncotype DX 21-gene recurrence score for HR+/HER2- breast cancer. Understand risk category and chemotherapy benefit based on TAILORx and RxPONDER trial evidence.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 - 25 through 0 - 25.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Integrate the result with invasive versus in-situ status, stage, receptor biology, treatment timing, genomic testing, comorbidity, and patient goals.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not interchange screening-risk, DCIS, invasive prognosis, genomic, and post-neoadjuvant tools.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment

How to apply this result

For a representative case, verify Recurrence Score, Nodal Status, Age / Menopausal Status, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Breast Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

BI-RADS Score (Breast)Nottingham Prognostic Index (NPI)MSKCC DCIS Nomogram — Breast Cancer DCIS Recurrence Risk Calculator

Frequently Asked Questions

When should Oncotype DX Recurrence Score Calculator — Breast Cancer Genomic Risk be used?

Use it for patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment when all required inputs and the intended clinical setting are confirmed.

Can Oncotype DX Recurrence Score Calculator — Breast Cancer Genomic Risk determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.